CNY:PA:PA-HSBC MSCI China UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 7.256

Change

+0.00 (+0.03)%

Market Cap

USD 0.62B

Volume

6.72K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.18 (+0.38%)

USD 55.36B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+1.40 (+0.25%)

USD 14.29B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+1.18 (+0.29%)

USD 13.82B
WRD:PA HSBC MSCI World UCITS ETF

+0.06 (+0.16%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-1.10 (-0.42%)

USD 9.11B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-2.60 (-0.52%)

USD 8.85B
WLD:PA Lyxor UCITS MSCI World D-EUR

+1.00 (+0.28%)

USD 7.99B
HHH:PA HSBC S&P 500 UCITS ETF

+0.14 (+0.24%)

USD 7.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

N/A

USD 6.91B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.03 (-0.43%)

USD 5.25B

ETFs Containing CNY:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.10% 97% N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.10% 97% N/A 88% B+
Trailing 12 Months  
Capital Gain 47.63% 98% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.63% 98% N/A 95% A
Trailing 5 Years  
Capital Gain -1.64% 18% F 40% F
Dividend Return 4.27% 7% C- 11% F
Total Return 2.63% 21% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -7.48% 5% F 21% F
Dividend Return N/A 28% F 20% F
Total Return N/A 60% D- 67% D+
Risk Return Profile  
Volatility (Standard Deviation) N/A 29% F 46% F
Risk Adjusted Return N/A 4% F 38% F
Market Capitalization 0.62B 69% C- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.